Specific Genetic Alterations Observed in Papillary Renal-Cell Carcinomas

This article originally appeared here.
Share this content:
Specific Genetic Alterations in Papillary Renal-Cell Carcinomas
Specific Genetic Alterations in Papillary Renal-Cell Carcinomas

(HealthDay News) -- Type 1 and type 2 papillary renal-cell carcinomas are characterized by specific genetic alterations, according to a study published online Nov. 4 in the New England Journal of Medicine.

W. Marston Linehan, M.D., from the National Cancer Institute in Bethesda, Md., and colleagues performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas. Whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis were conducted.

The researchers found that types 1 and 2 papillary renal-cell carcinomas were characterized by specific genetic alternations, with type 2 subclassified into three individual subtypes based on molecular differences that correlated with patient survival. MET alterations were seen in association with type 1 tumors. CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element pathway characterized type 2 tumors. A distinct subtype of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the fumarate hydratase gene exhibited a CpG island methylator phenotype.

"Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct," the authors write. "Type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features."

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs